Treat vaccine of sexual second liver: Hope and predicament

By the whole nation heavy-duty liver disease and artificial liver blood are purified tackle key problem synergic group, China medicine can continue science and technology of medicine of cure of foundation of prevention and cure of hepatitis of Ministry of Education, China and precautionary technology referral center, Beijing develops association to be held jointly " difficulty of the first whole nation is heavy-duty liver disease congress and the 4th, at coming 6 days to be in on September 3, 2008 Jiangxi Nanchang is held. Join many 1000 meeting scholar. The conference with respect to course of across of difficulty liver disease, heavy-duty liver disease, liver disease clinical and practical technology reachs the side such as research progress, special invite domestic and international expert to undertake special subject reports, this period " digestive weekly " D1~D3 carries a share wonderful congress report, return subsequently will in succession print gives congress photograph inside Shanghaiguan to allow, pay close attention to please. The end that treats sexual vaccine is revulsive cell of CD4+T of stimulation of factor of phlogistic sex cell and cell of cellular noxiousness T (CTL) is respondent, break immunity to be able to bear or endure suffer, rebuild or enhance immunity respondent, restrain virus to duplicate thereby. Current, the research of vaccine of sex of second liver cure basically is centered at albumen vaccine and DNA vaccine, former include complex matter vaccine, list vaccine, all gain certain headway. the part new-style vaccine and disease-resistant bane content combine application, to cure chronic second liver brought new hope. The curative effect of vaccinal have an inoculation suffers the person that try in health already got confirming in research, however, in virus of chronic second liver (this curative effect is not long in HBV) infection patient. The main problem that solves urgently at present is, effective cellular immunity is respondent need stimulates a lot of antigen and be to be aimed at virus coating not simply. What deserve a consideration likewise is DC vaccine, watch complex matter vaccine gives antibody of vaccine and antigen medical pattern optimize, should with can effective carry to immune system show antigen to be target to. After all whether does immune therapeutics medication than pure disease-resistant poison more effective, have pair of person that carry chronically and rehabilitation patient only the ceaseless exploration of relevant element, ability gets determining the result. Besides, vaccine is in problem of the true and potential effect in human body, security, and excessive is revulsive immunity is respondent the possibility that creates hepatitis aggravation should be inside consideration limits. Albumen vaccine 　 is inchoate and clinical antigen of the S1 before studying what be centered at using HBV more (PreS1) and S antigen will activation T cell is respondent, its curative effect is finite. Hind through increasing HBV antigen, blame structural albumen is expressed, change vaccinal form or complementary form new-style vaccine with the way such as new-style assistant agent, divide but outside function of immunity of rapid and revulsive cell, still can raise humoral immunity respondent (Th2 immunity is respondent) in order to increase protection antibody. Inferior the PreS1 in albumen of HBV of 　 of unit vaccine 　 , before S2 antigen (antigen of PreS2) , S and antigen of second liver core (the either combination of HBcAg) , through yeast other perhaps expression of true nucleus cell formed remedial sex inferior the unit is vaccinal. Researcher parts to crowd of patient of liver of different and chronic second have an inoculation recombines 3 kinds fight HBV vaccine to undertake study, these 3 kinds of vaccine are antigen of surface of liver of PreS2/S, second respectively (combination of HBsAg)/PresS2, Pres2/PreS1/S. The result shows, the HBV DNA that PreS2/S vaccine treats group patient turns shade leads remarkable prep above to contrast group, but after cure ends 1 year, its HBV DNA turns rate of shade rate, HBeAg serum changeover does not have significance heighten. HBsAg/PresS2 vaccine is vaccinal 1 year half hind, still can detect cell of proliferous sex T is respondent, still partial patient is in below the circumstance that lacks CTL activity, can detect many γ interferon (IFN γ ) with tumor necrotic factor α (TNF α ) generate. Pres2/PreS1/S vaccine has improvement hepatic histology pathological changes, increase nature to kill and wound (γ of NK) cell amount, stimulative IFN is generated reach reduce Bai Jiesu (the action of IL)-10 level. Antigen of change of complex matter vaccinal 　 carries immunity show means to strengthen immune former sex and adjusting control respondent type, it is the another way that remedial sex vaccine studies. By recombine HBsAg and the antigen that fight combination of HBs immunity globulin - complex matter vaccine can pass antibody immunity the main organization consistence that enhances FcR interpose to guide is compound body (MHC)- Ⅰ kind carry show a way, raise antigen to carry show a cell (of APC) capture and extract ability, enhance the result of immune former sex of HBsAg thereby, increase the generation that fights cell of HBs particularity T. Polypeptide is vaccinal (express a vaccine) antigen of 5 　 albumen machines processing finally to become through APC express a polypeptide, be united in wedlock with MHC element, be identified by particularity T cell thereby and invoke immunity respondent reaction. The scholar thinks this kind of effective protection depends on a group of antigen are expressed combination and collocation. Express to antigen element in recent years research makes new research way. Tree dash forward sex of cure of 　 of shape cell vaccine is cultivated dash forward shape cell (the person that DC) vaccine uses chronic HBV to carry from body DC stronger antigen is carried show ability, antigen of laden HBV particularity, enhance the first signal of T cell activation already, can go up again the expression of element of the surface that move DC, auxiliary and exciting element generates the 2nd signal with T cell indispensible activation. The scholar discovers DC vaccine and rummy husband decide associated application to be able to keep clear of effectively HBV. Assistant agent treats the assistant agent that hydroted alumina regards sexual vaccine 　 as to recombine HBsAg vaccine at present, its effectiveness and security already got a proof, but the cleared action that infects a cell to HBV is limited. Consider to make clear, the few that new-style assistant agent is not the methylic pyrimidine that change afterbirth and acid of bird purine nucleotide to be core gets together deoxidization nucleic acid (CpG ODN) can activation the Toll R9 of APC surface, the Th1 such as α of revulsive generation IL-12, TNF cell factor that give priority to. "The DNA vaccine of newest research of vaccinal 　 of 　 　 DNA is get on the DNA load of HBsAg at plasmid, its can synthesize antigen afresh inside vaccinal patient system, eliminate inject and inverting risk, stimulate immune active cell repeatedly, produce the humoral immunity of as similar as the vaccine that decrease work result and cellular immunity. In addition, the immunity on plasmid backbone is excitant blame is methylic change CpG the dot can make DNA vaccine is had inside embedded assistant agent, cause T cell two polarization, generation Th1 is respondent, generate IFN α thereby, the cellular factor such as IFN γ and TNF α . In a research of foreign scholar, 10 existing cure are respondent not the person that the chronic HBV of beautiful is affected accepts flesh to note DNA vaccine, worsen for the disease except 2 patients expression (did not appear liver fails) outside, the others all is able to bear or endure suffer good. All patients all appear of virus DNA level reduce and antigen of second liver E (HBeAg) serum changeover, still detect at the same time level of γ of serum IFN is elevatory. Clinical trial is undertaking additionally two Ⅰ period. A test that has in Gambia shows, gene vaccine is not revulsive a cell of HBV particularity T that can detect, however, the person that HBeAg negative is carried chronically especially virus carries the patient with inferior quantity, after be strengthened through recombining vaccine, can be detected particularity cell immunity is respondent. After 6 months, although the patient is OK to vaccinal have an inoculation better be able to bear or endure suffer, fail to be detected to give a cell again however respondent. The person that a research that has in Lithuania evaluated 12 chronic HBV to carry accepts rummy husband to combine remedial result with vaccine surely. All sufferring the person that try is right the DNA that codes albumen of 3 HBV coating reachs IL-12 is vaccinal but better be able to bear or endure suffer, 8 patients in end second vaccine injects hind, virus DNA negative can last 1 year above, in the meantime, serum IL-12 chroma of the patient lifts somewhat. (the exercitation edits: Plum apricot)